Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Repair Protein Expression in Canine Cutaneous Mast Cell Tumors
Cutaneous mast cell tumors (MCTs) are common canine neoplasms. Some dog breeds more frequently develop MCTs, suggesting a genetically mediated predisposition. In humans, the most common inherited cancer predisposition is caused by germline defects in the mismatch repair (MMR) genes. Is the same true for dogs?

The objective of this study was to investigate whether inherited defects in the MMR genes predispose some dogs to MCT development, MMR expression in 22 MCTs from young and predisposed breed dogs was compared with MMR expression in 22 MCTs from old dogs of non-MCT-predisposed breeds. MMR expression was investigated immunohistochemically using antibodies against MLH1, MSH2, and MSH6.

Mast cells within all MCTs expressed MLH1, MSH2, and MSH6.

There were no significant differences in the intensity of immunoreactivity or the percentage of cells expressing MMR proteins between MCTs from the 2 groups of dogs.

There were no significant differences in MMR protein expression between grade II and grade III MCTs. These results do not support the hypothesis that inherited MMR defects predispose some dogs to MCT development.


Source: J. S. Munday, A. F. French, I. R. Gibson and K. Gwynne (2009): Widespread Mismatch In: Vet Pathol 46:227-232 (2009)




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Tolerability of a rapid-escalation vinblastine-prednisolone protocol in canine mast cell tumoursmembers
Optimal chemotherapy protocols for high-risk mast cell tumours (MCTs) are unknown. The purpose of this study was to determine the tolerability and toxicity profile of a rapidly escalating vinblastine and prednisolone protocol (VPP) in which 3.00 mg/m2 was administered once 7 days apart: at day 14 and at day 21.

  • Retrospective Study of Feline Exocrine Pancreatic Insufficiencymembers
  • Prevention of laryngospasm with rocuronium in anesthetized catsmembers
  • Translaryngeal percutaneous arytenoid lateralization technique in dogsmembers
  • 2-tier histologic grading system for canine cutaneous mast cell tumors on cytology members
  • Dynamic sonography of the metacarpophalangeal digital flexor tendon sheath in horsesmembers
  • Improved survival in patients undergoing pulmonary metastasectomy for sarcomamembers
  • LDE tendon mineralization with concurrent cruciate ligament rupturemembers
  • Role of IL-4 in neoplastic canine mast cellsmembers
  • Cryopreserved platelet concentrate transfusions in 43 dogsmembers
  • CT comparison of intranasal features in brachycephalic and normocephalic dogsmembers
  • Comparison of 2 Doses for ACTH Stimulation Testing in Dogs members
  • NT-proBNP and cardiac troponin I in dogs with tick paralysis due to I. holocyclusmembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved